NEW YORK, Nov. 30, 2017 /PRNewswire/ -- In keeping with the commitment to dynamically provide members with timely information,WallStEquities.com has issued free tailored Stock Review on FGEN, GBT, ICPT, and NKTR which is a click away at www.wallstequities.com/registration. WallStEquities.com is currently focused on the following stocks: FibroGen Inc. (NASDAQ: FGEN), Global
FibroGenSan Francisco, California headquartered FibroGen Inc.'s stock finished Wednesday's session 0.74% lower at $46.95 with a total trading volume of 379,159 shares. The Company's shares have advanced 1.08% in the previous three months and 119.39% since the start of this year. The stock is trading 27.03% above its 200-day moving average. Additionally, shares of FibroGen, which discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs in the US, have a Relative Strength Index (RSI) of 35.34.
On November 08th, 2017, FibroGen reported its financial results for Q3 2017. Total revenue for Q3 2017 was $27.3 million, loss from operations was $36.0 million, and net loss was $37.7 million. At September 30th, 2017, the Company had cash and cash equivalents of $651.4 million. The free report on FGEN can be accessed at: www.wallstequities.com/registration/?symbol=FGEN
Global Blood TherapeuticsOn Wednesday, shares in South San Francisco, California headquartered Global Blood Therapeutics Inc. recorded a trading volume of 670,365 shares. The stock ended the session 4.71% lower at $37.40. The Company's shares have surged 30.77% in the previous three months and 158.82% on an YTD basis. The stock is trading 7.54% above its 50-day moving average and 20.58% above its 200-day moving average. Moreover, shares of the Company, which engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood-based disorders, have an RSI of 48.43.
On November 13th, 2017, Global Blood Therapeutics announced that the independent Data and Safety Monitoring Board for the Phase 3 HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymErization) Study evaluating voxelotor (previously called GBT440) for the treatment of sickle cell disease (SCD), has completed its first scheduled clinical safety review. No drug-related serious or severe adverse events were reported in either of the voxelotor treatment arms (900 mg and 1500 mg), and there were no discontinuations due to adverse events. Download our actionable research report on GBT at: www.wallstequities.com/registration/?symbol=GBT
Intercept PharmaceuticalsNew York headquartered Intercept Pharmaceuticals Inc.'s shares closed the day 1.66% higher at $60.13. The stock recorded a trading volume of 680,078 shares. The Company's shares are trading 7.26% below their 50-day moving average. Additionally, shares of Intercept Pharma, which focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases, have an RSI of 47.00.
On November 01st, 2017, research firm Laidlaw upgraded the Company's stock rating from 'Hold' to 'Buy', with a target price of $90 per share.
On November 27th, 2017, Intercept Pharma announced the appointment of Christian Weyer, M.D., M.A.S., as Executive Vice President – R&D, reporting to Dr. Mark Pruzanski, President and CEO. Dr. David Shapiro will continue in his role as Chief Medical Officer. Register for your free report coverage on ICPT at: www.wallstequities.com/registration/?symbol=ICPT
Nektar Therapeutics Shares in San Francisco, California headquartered Nektar Therapeutics finished 3.88% higher at $54.14. The stock recorded a trading volume of 2.84 million shares, which was higher than its three months average volume of 1.96 million shares. The Company's shares have skyrocketed 130.28% in the last one month, 177.50% in the previous three months, and 341.24% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 85.43% and 149.37%, respectively. Furthermore, shares of Nektar Therapeutics, which develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the US, have an RSI of 92.31.
On November 07th, 2017, Nektar Therapeutics reported its financial results for the third quarter ended September 30th, 2017. Revenue in Q3 2017 was $152.9 million, total operating costs and expenses were $83.4 million, and net income was $60.9 million. Cash and investments in marketable securities at September 30th, 2017 were $412.2 million.
On November 13th, 2017, research firm Mizuho reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $30 a share to $45 a share. Get the free research report on NKTR at: www.wallstequities.com/registration/?symbol=NKTR
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit: https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: [email protected] Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/this-mornings-research-reports-on-biotechnology-stocks----fibrogen-global-blood-therapeutics-intercept-pharma-and-nektar-therapeutics-300564234.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Strokes occur when blood flow to an area of the brain is cut off. It is imperitive to detect the ...
Bile duct cancer occurs either within the liver or the point where the bile ducts emerge from the ...
Xeroderma pigmentosum is a rare inherited condition marked by extreme sensitivity to sunlight and ...View All